The HDAC1 Knockout KYSE-30 Polyclonal Cells consist of a heterogeneous population of human KYSE-30 esophageal squamous cell carcinoma cells engineered through CRISPR/Cas9-mediated disruption of the HDAC1 gene, encoding histone deacetylase 1. As a polyclonal knockout pool, this product contains cells with varied editing outcomes, reflecting the typical diversity of a non-clonal editing strategy. It provides a reliable loss-of-function model for investigating HDAC1-dependent epigenetic and transcriptional regulation in a cancer cell context.
The host cell line KYSE-30 was established from a poorly differentiated esophageal squamous cell carcinoma of a Japanese male and retains wild-type TP53. This line exhibits an epithelial phenotype and is widely employed in esophageal cancer research for exploring tumor suppressor pathways, drug response mechanisms, and the molecular basis of squamous cell carcinoma. The wild-type TP53 status is particularly advantageous for studying p53-mediated processes without mutant-p53 interference.
HDAC1 catalyzes the removal of acetyl groups from histone H3 and H4 tails, condensing chromatin and repressing transcription. It functions as the catalytic component of repressor complexes such as SIN3A/NCoR (binding SIN3A), NuRD (with MTA2, CHD4, RbAp46/48, MBD2), and CoREST (via RCOR1). Regulation occurs upstream through MYC and E2F1 and via CK2 phosphorylation and sumoylation. Substrates include TP53, pRB, and BCL6, and it represses CDKN1A (p21) expression. HDAC1 knockout results in hyperacetylated histones, derepressed tumor suppressors, and impaired cell cycle and apoptosis signaling.
Within the KYSE-30 esophageal cancer background, loss of HDAC1 provides a powerful tool for assessing the functional consequences of HDAC1 deficiency in a TP53-competent setting. This model is particularly relevant for studying epigenetic mechanisms of tumorigenesis, as it allows separation of HDAC1-specific effects from those of mutant p53. The polyclonal nature of the knockout population also enables analysis of phenotypic heterogeneity and average responses to HDAC-targeted agents, making it suitable for drug sensitivity screens and chromatin biology studies.
Common applications include Western blotting for acetyl-histone H3/H4, RT-qPCR for CDKN1A or BCL6, ChIP-qPCR for histone acetylation, cell viability and apoptosis (Annexin V) assays, migration/invasion studies, and HDAC inhibitor sensitivity testing. The product supports epigenetic research, functional genomics, and drug target validation in esophageal cancer. For further details, contact Ascent Research.
